Napabucasin
- Generic Name
- Napabucasin
- Drug Type
- Small Molecule
- Chemical Formula
- C14H8O4
- CAS Number
- 83280-65-3
- Unique Ingredient Identifier
- Z1HHM49K7O
- Background
Napabucasin has been investigated for the treatment of Colorectal Carcinoma.
BBI608 and Best Supportive Care vs Placebo and Best Supportive Care in Pretreated Advanced Colorectal Carcinoma
- Conditions
- Colorectal Carcinoma
- Interventions
- First Posted Date
- 2013-04-12
- Last Posted Date
- 2023-08-28
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 282
- Registration Number
- NCT01830621
- Locations
- π¨π¦
Tom Baker Cancer Centre, Calgary, Alberta, Canada
π―π΅Chiba Cancer Center, Chiba, Japan
π¦πΊSt John of God - Subiaco, Subiaco, Western Australia, Australia
A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2013-01-28
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 200
- Registration Number
- NCT01776307
- Locations
- πΊπΈ
USOR - Texas Oncology Tyler, Tyler, Texas, United States
πΊπΈAbramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
πΊπΈUS Oncology Research, The Woodlands, Texas, United States
A Study of BBI608 in Adult Patients With Advanced Malignancies
- First Posted Date
- 2013-01-25
- Last Posted Date
- 2023-11-14
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 87
- Registration Number
- NCT01775423
- Locations
- π¨π¦
Jewish General Hospital, Montreal, Quebec, Canada
πΊπΈInstitute for Translational Oncology Research, Greenville Hospital System, Greenville, South Carolina, United States
π¨π¦Ottawa Hospital Cancer Center, Ottawa, Ontario, Canada
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
- First Posted Date
- 2011-03-29
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 565
- Registration Number
- NCT01325441
- Locations
- πΊπΈ
Texas Oncology- Fort Worth, Fort Worth, Texas, United States
π¨π¦British Columbia Cancer Agency, Vancouver, British Columbia, Canada
πΊπΈVirginia Cancer Specialists, P.C., Fairfax, Virginia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.